Navigation Links
ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
Date:2/19/2008

WELLESLEY HILLS, Mass., Feb. 19 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today the design of a clinical trial to investigate whether Chlamydia STD is treated adequately by currently approved antibiotics. Rifalazil, the most potent anti-chlamydial agent that has been administered to people, may provide a better treatment option for Chlamydia STD. The insidious aspect of Chlamydia STD is that infections which are inadequately treated can later result in serious consequences. A new, improved treatment would prevent the long-term detrimental effects of Chlamydia STD, which for women include mucopurulent cervicitis, pelvic inflammatory disease, ectopic pregnancy, and infertility. Chlamydia STD infections have also been associated with increased transmission of human immunodeficiency virus (HIV) in both men and women.

At the present time, the prevailing medical opinion is that Chlamydia STD is treated adequately by a single 1 gram oral dose of azithromycin. However, in a previous Phase II clinical trial (published in 2007 in the journal Sexually Transmitted Diseases), men experiencing symptoms of nongonococcal urethritis attributed to Chlamydia trachomatis infection had higher cure rates with rifalazil than with azithromycin five weeks after treatment. Although the sample size of the trial was small, these results certainly left room to consider the possibility of an improved therapy with rifalazil for treating all Chlamydia STDs.

The new trial would compare a group of women, all infected with Chlamydia STD, who would be administered a single oral dose of rifalazil with a similar group receiving a single dose of azithromycin. "We can examine if rifalazil is superior to azithromycin in eradicating Chlamydia STD in women by evaluating 55 subjects in each treatment group", said Walter Stamm from the University of Washington, a leading clinician in the area of Chlamydia STD. Indeed, suc
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
2. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
6. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
7. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Maine Natural Health Company Conducts Dental Clinical Trial
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Minn., March 10 Here are highlights from the March ... cite this publication as often as you wish. Reprinting is ... attribution is required. Include the following ... www.HealthLetter.MayoClinic.com or call toll-free for subscription ...
... Avineuro Pharmaceuticals, Inc. announced today an initiation of ... selective small molecule antagonist of 5-HT6 receptor for treatment ... expected to be available in April 2009. Based on ... advance AVN-211 into Phase II clinical trials in Q2 ...
Cached Medicine Technology:March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 2March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 3March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 4March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 5
(Date:11/27/2014)... New Albany, IN (PRWEB) November 27, 2014 ... dental implant clinic, has a few oral health tips ... Dr. Receveur, who offers Louisville and New Albany affordable ... mountains of foods high in starch and sugar. While the ... practice has some helpful tips for how patients can enjoy ...
(Date:11/27/2014)... Burnsville MN (PRWEB) November 27, 2014 ... manufacturer of office ergonomics equipment , has announced ... partnership with Commercial Office Environments. The partnership will ... for office furnishings location. , In addition to ... the new dealer partnership promotes HealthPostures' products with ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Allowing children to ... even during school, helps give children responsibility, ownership, boosts self-esteem, ... , Now, the real question is, how do ... a secret? According to a study published by Child Development ... have a dramatic effect on a child’s willingness to lend ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, ... announced online reputation management service. , The ... study about the world of internet marketing and algorithms ... , Ethane Web Technologies does not work with ... analyzes the project to reach a conclusion what will ...
Breaking Medicine News(10 mins):Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2
... a waiting list, can reduce problems with recurring low back ... Many people suffer with low back pain, and most ... find that their work, everyday and leisure activities are limited ... treatment, it is important that the pain be treated at ...
... Food and Drug Administration (FDA) approval of a brain aneurysm ... Jefferson Hospital for Neuroscience (JHN) to offer advanced ... otherwise have limited, effective options. "With this FDA approval, ... tool to block and shrink these types of aneurysms, saving ...
... Indiana soon will partner with colleagues in Ohio ... working across state lines to advance research on ... program, supported by the Indiana Clinical and Translational ... across the region, including Indiana University Health Riley ...
... Prozac: new drug offers hope for depression ... from depression, and though the symptoms might be ... incompletely understood. Research suggests that aberrant signaling by ... its receptor TrkB, may contribute to anxiety and ...
... Vancouver,s Downtown Eastside dropped by 35 per cent after ... facility, according a new study by researchers at the ... for Excellence in HIV/AIDS. Published today in The ... assess the impact of supervised injection sites on overdose ...
... Psychologists are offering new insight and solutions ... with the environmental, economic and health impacts already taking ... issue of American Psychologist , the American Psychological ... for and in many cases is already affecting ...
Cached Medicine News:Health News:Immediate treatment can alleviate future back problems 2Health News:FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool 2Health News:Children's doctors team up across state lines to fight disease 2Health News:JCI online early table of contents: April 18, 2011 2Health News:JCI online early table of contents: April 18, 2011 3Health News:JCI online early table of contents: April 18, 2011 4Health News:JCI online early table of contents: April 18, 2011 5Health News:JCI online early table of contents: April 18, 2011 6Health News:JCI online early table of contents: April 18, 2011 7Health News:Overdose deaths down 35 percent after opening of Vancouver's supervised injection site: UBC-BC-CfE study 2Health News:Climate change psychology: Coping and creating solutions 2Health News:Climate change psychology: Coping and creating solutions 3
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: